Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Julphar
Dow
Colorcon
Queensland Health
Boehringer Ingelheim
Deloitte
Argus Health
Fish and Richardson

Generated: January 21, 2019

DrugPatentWatch Database Preview

Tentative Approvals for: Cipla

« Back to Dashboard

Cipla Drugs with Tentative Approvals

Applicant Generic Name NDA Strength Dosage Form
Cipla Limited efavirenz; emtricitabine; tenofovir disoproxil fumarate 091593 200MG TABLET; ORAL
Cipla Limited lamivudine; zidovudine 202814 30MG; 60MG TABLET, FOR SUSPENSION; ORAL
Cipla Limited abacavir sulfate 078348 20MG SOLUTION; ORAL
Cipla Limited lamivudine; zidovudine 201151 30MG; 60MG TABLET; ORAL
Cipla Limited efavirenz 077916 600MG TABLET; ORAL
Applicant Generic Name NDA Strength Dosage Form

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Federal Trade Commission
Citi
UBS
Merck
AstraZeneca
McKinsey
Covington
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.